arrow
A

Aditya Juloori

university of chicago
H指数:21
被引数:2,634

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

American Radium Society Appropriate Use Criteria: Accelerated hypofractionated radiotherapy in the multidisciplinary management of locally-advanced non-small cell lung cancer ineligible for concurrent chemotherapy

美国镭协会适宜应用标准:在多学科管理中,对不适合同步化疗的局部晚期非小细胞肺癌采用加速低分割放射治疗

2026-10-130
PRE
Practice Patterns in Management of Low- to Intermediate-Grade Salivary Gland Carcinoma: A Multi-Institutional Study

低级别至中级别唾液腺癌的管理实践模式:一项多机构研究

2025-09-230
OAAI
Corrigendum to “Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas”. [Oral Oncol. 163 (2025) 107207]

勘误:“Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas” [Oral Oncol. 163 (2025) 107207]

2025-07-280
PRE
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer The DEPEND Phase 2 Nonrandomized Clinical Trial

新辅助纳武利尤单抗联合化疗后序贯基于应答分层的放化疗在HPV阴性头颈癌中的DEPEND II期非随机临床 trial

2025-05-011
PRE
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas

AI基础模型特征的分析解码了HPV阳性头颈部鳞状细胞癌的组织病理学景观

2025-03-011
PRE
Head and Neck Cancers, Version 2.2025 Featured Updates to the NCCN Guidelines

头颈癌,版本2.2025:NCCN指南特色更新

2025-02-012
PRE
Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer
2024-05-230
OAAI
Non-Small Cell Lung Cancer, Version 4.2024

非小细胞肺癌4.2024版

2024-05-0150
PRE
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

晚期/不可切除肝细胞癌立体定向放射治疗后Nivolumab加Ipilimumab或单独Nivolumab的1期随机试验

2023-01-0139
PRE
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
2022-08-094
OA